AI Engines For more Details: Perplexity Kagi Labs You
Antiviral Activity: Idoxuridine exerts its effects by inhibiting the replication of DNA viruses, including herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). It interferes with viral DNA synthesis, thereby preventing the virus from multiplying and spreading within the body.
Treatment of Ocular Herpes Infections: Idoxuridine is commonly used as a topical ophthalmic solution for the treatment of herpes simplex keratitis, a viral infection of the cornea caused by HSV. It helps reduce the severity and duration of symptoms such as eye pain, redness, inflammation, and corneal ulceration associated with ocular herpes infections.
Prevention of Herpes Recurrences: In addition to treating active herpes infections, idoxuridine may also be used prophylactically to prevent recurrent episodes of herpes simplex keratitis in individuals with a history of frequent recurrences.
Side Effects: Common side effects of idoxuridine ophthalmic solution include temporary stinging or burning sensation upon instillation, eye irritation, redness, itching, and blurred vision. These side effects are usually mild and transient.
Ocular Toxicity: Prolonged or excessive use of idoxuridine ophthalmic solution may lead to ocular toxicity, characterized by corneal epithelial toxicity, punctate keratitis, conjunctival hyperemia, and allergic reactions. Long-term use should be avoided to minimize the risk of ocular adverse effects.
Systemic Absorption: While idoxuridine is primarily administered topically to the eyes, systemic absorption can occur, especially if the medication is used in large quantities or for an extended duration. Systemic absorption may lead to systemic side effects, although they are rare.
Contraindications: Idoxuridine ophthalmic solution is contraindicated in individuals with known hypersensitivity or allergy to idoxuridine or any of its components. It should also be used with caution in patients with pre-existing ocular conditions or compromised immune function.
Pregnancy and Lactation: The safety of idoxuridine use during pregnancy and lactation has not been established. It should only be used if the potential benefits outweigh the risks and under the supervision of a healthcare provider.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.7 | 0.7 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 2.6 | 0.3 | 7.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 1.8 | 2 | -0.11 |
| Allergies | 2.5 | 1.5 | 0.67 |
| Allergy to milk products | 1.4 | 1.2 | 0.17 |
| Alzheimer's disease | 3.3 | 4.9 | -0.48 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.1 | 0.6 | 2.5 |
| Ankylosing spondylitis | 2.7 | 0.4 | 5.75 |
| Anorexia Nervosa | 0.8 | 2.2 | -1.75 |
| Antiphospholipid syndrome (APS) | 1.9 | 1.9 | |
| Asthma | 3.4 | 1.6 | 1.13 |
| Atherosclerosis | 1.8 | 1.7 | 0.06 |
| Atrial fibrillation | 1.8 | 1.8 | 0 |
| Autism | 4.9 | 4.9 | 0 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.6 | 1.6 | |
| Bipolar Disorder | 1.1 | 0.8 | 0.38 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.3 | 1.8 | -5 |
| Carcinoma | 1.7 | 0.9 | 0.89 |
| Celiac Disease | 2.5 | 0.9 | 1.78 |
| Cerebral Palsy | 1.1 | 0.8 | 0.38 |
| Chronic Fatigue Syndrome | 2.8 | 2 | 0.4 |
| Chronic Kidney Disease | 1.8 | 0.8 | 1.25 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 | 1.1 | 0.82 |
| Chronic Urticaria (Hives) | 1.7 | 1.2 | 0.42 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 0.8 | 0.88 |
| Cognitive Function | 0.9 | 1.6 | -0.78 |
| Colorectal Cancer | 5.2 | 2.2 | 1.36 |
| Constipation | 1 | 0.5 | 1 |
| Coronary artery disease | 1.6 | 2 | -0.25 |
| COVID-19 | 4.6 | 6.1 | -0.33 |
| Crohn's Disease | 4.6 | 2.3 | 1 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1.2 | 1.3 | -0.08 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.1 | 1.1 | 0.91 |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 5.9 | 3.7 | 0.59 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.2 | 1.7 | -0.42 |
| Endometriosis | 2.3 | 1.7 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 3.3 | 0.6 | 4.5 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 1 | 1.9 | -0.9 |
| Functional constipation / chronic idiopathic constipation | 4.5 | 3.4 | 0.32 |
| gallstone disease (gsd) | 2.1 | 0.8 | 1.63 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.3 | 1.33 |
| Generalized anxiety disorder | 2.2 | 1.4 | 0.57 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.8 | 0.5 | 2.6 |
| Graves' disease | 0.6 | 1.7 | -1.83 |
| Gulf War Syndrome | 0.8 | 1.6 | -1 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.7 | 0.6 | 1.83 |
| Heart Failure | 2.5 | 0.8 | 2.13 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 1.9 | 0.3 | 5.33 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 1.1 | |
| hyperglycemia | 1.4 | 0.6 | 1.33 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 1.5 | 4.1 | -1.73 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 2.6 | 0.3 | 7.67 |
| IgA nephropathy (IgAN) | 0.6 | 3.5 | -4.83 |
| Inflammatory Bowel Disease | 5.2 | 4.6 | 0.13 |
| Insomnia | 1.1 | 1.1 | 0 |
| Intelligence | 1.8 | 0.6 | 2 |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 4.8 | 3 | 0.6 |
| ischemic stroke | 1.5 | 1.4 | 0.07 |
| Liver Cirrhosis | 4.8 | 2.5 | 0.92 |
| Long COVID | 3.4 | 2.6 | 0.31 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.2 | 1.2 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.5 | 0.7 | -0.4 |
| ME/CFS without IBS | 0.6 | 0.6 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.1 | 0.5 | 1.2 |
| Metabolic Syndrome | 4.7 | 4.5 | 0.04 |
| Mood Disorders | 5.8 | 2.7 | 1.15 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
| Multiple Sclerosis | 2.9 | 3.7 | -0.28 |
| Multiple system atrophy (MSA) | 1.2 | 0.3 | 3 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.4 | -2.4 | |
| Neuropathy (all types) | 0.3 | 1.7 | -4.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4 | 1.9 | 1.11 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 6.3 | 3.8 | 0.66 |
| obsessive-compulsive disorder | 3.6 | 2.2 | 0.64 |
| Osteoarthritis | 1.9 | 0.9 | 1.11 |
| Osteoporosis | 1.6 | 0.6 | 1.67 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 4.3 | 4.2 | 0.02 |
| Polycystic ovary syndrome | 3.3 | 1.9 | 0.74 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.3 | 0.9 | -2 |
| Primary sclerosing cholangitis | 1.4 | 0.6 | 1.33 |
| Psoriasis | 2 | 1.7 | 0.18 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 2.5 | 0.24 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 2.9 | 1.6 | 0.81 |
| scoliosis | 0.9 | 0.9 | |
| Sjögren syndrome | 1.8 | 1.1 | 0.64 |
| Sleep Apnea | 0.6 | 1.1 | -0.83 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 0.1 | 16 |
| Stress / posttraumatic stress disorder | 1.9 | 1.4 | 0.36 |
| Systemic Lupus Erythematosus | 2.7 | 1.3 | 1.08 |
| Tic Disorder | 0.7 | 0.9 | -0.29 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2.9 | 2.3 | 0.26 |
| Type 2 Diabetes | 4.9 | 4.8 | 0.02 |
| Ulcerative colitis | 3.5 | 5.6 | -0.6 |
| Unhealthy Ageing | 1.8 | 1.4 | 0.29 |
| Vitiligo | 1.5 | 0.6 | 1.5 |
